A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59 (R) Adjuvant
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs Influenza A virus H7N9 vaccine Seqirus (Primary) ; MF 59
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions; Pharmacodynamics
- 21 Nov 2019 Planned End Date changed from 30 Nov 2019 to 22 Apr 2020.
- 21 Nov 2019 Planned primary completion date changed from 30 Nov 2019 to 22 Apr 2020.
- 21 Nov 2019 Status changed to active, no longer recruiting.